CatalYm to Present Early Phase 2a Data on GDF-15 Neutralizing Antibody Visugromab at the 2023 ASCO Annual Meeting

Oral presentation in "Developmental Therapeutics-Immunotherapy" session on Sunday, June 4 at 9:45 AM CDT CatalYm today announced that the first results from its ongoing Phase 2a trial "GDFATHER-2"

Related Keywords

Chicago ,Illinois ,United States ,American ,Ignacio Melero Bermejo ,Gewinn Nur ,Catalym Gmb ,Phil Lhuilier ,Trophic Communications ,American Society Of Clinical Oncology ,Ted Human Effector Cell Relocation Phase ,American Society ,Clinical Oncology ,Annual Meeting ,Universidad De Navarra ,Ted Human Effector ,Relocation Phase ,Growth Differentiation ,Phill Huilier ,Stephanie May ,